---
title: "Pfizer (United States): research papers"
description: "From 2017 to 2026 (so far), authors at Pfizer (United States) took part in 40 papers in the tracked journals, most of them in health economics and policy (37), economics (1) and statistics (1). 3 of them were published in 2025, against 3 in 2017."
url: https://scholar4ai.com/companies/pfizer-united-states
markdown_url: https://scholar4ai.com/companies/pfizer-united-states.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Pfizer (United States) took part in 40 papers in the tracked journals, most of them in health economics and policy (37), economics (1) and statistics (1). 3 of them were published… (as of 2026-10-31)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-10-31T19:11:11+09:00
window: 2026-10-02 to 2026-10-31
source: OpenAlex (CC0)
---

# Pfizer (United States)

Papers in the tracked journals with an author at Pfizer (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Pfizer (United States) took part in 40 papers in the tracked journals, most of them in health economics and policy (37), economics (1) and statistics (1).
- 3 of them were published in 2025, against 3 in 2017.
- Since 2023, the institutions with the most of these papers were Pfizer (United Kingdom) (6), Merck Healthcare KGaA, Darmstadt (Germany) (2) and Nemours Children's Health System (2).
- The journals publishing most of them were PharmacoEconomics - Open (6), PharmacoEconomics (5) and Cost Effectiveness and Resource Allocation (5).
- The most-cited of them is “Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment” (PharmacoEconomics, 2020), with 101 citations.
- Since 2023, papers in the tracked journals cited 11 of its papers 18 times; 89% of those links came from papers with a university author and 11% from its own papers.
- Its own papers since 2023 cite archived papers 33 times, 24% of them papers with a company author.

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 2 | 1 | 3 | 4 | 7 | 2 | 4 | 6 | 3 | 5 |
| [Economics](https://scholar4ai.com/categories/economics.md) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| [Finance](https://scholar4ai.com/categories/finance.md) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| All categories | 3 | 1 | 3 | 5 | 8 | 2 | 4 | 6 | 3 | 5 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 6 |
| 2 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 5 |
| 3 | [Cost Effectiveness and Resource Allocation](https://scholar4ai.com/journals/cost-effectiveness-and-resource-allocation.md) | 5 |
| 4 | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 1 |
| 5 | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | Pfizer (United Kingdom) | 6 |
| 2 | Merck Healthcare KGaA, Darmstadt (Germany) | 2 |
| 3 | Nemours Children's Health System | 2 |
| 4 | AbbVie (United Kingdom) | 1 |
| 5 | Astellas Pharma (United States) | 1 |
| 6 | Carelon Research (United States) | 1 |
| 7 | GlaxoSmithKline (United States) | 1 |
| 8 | Guy's and St Thomas' NHS Foundation Trust | 1 |
| 9 | Health Economics and Outcomes Research (United Kingdom) | 1 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United States | 18 |
| 2 | United Kingdom | 8 |
| 3 | Germany | 3 |
| 4 | Australia | 1 |
| 5 | Canada | 1 |
| 6 | Switzerland | 1 |
| 7 | Colombia | 1 |
| 8 | Ireland | 1 |
| 9 | Sweden | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | quality-adjusted life years | 6 |
| 2 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 5 |
| 3 | PCV20 | 3 |
| 4 | economic burden | 3 |
| 5 | first-line therapy | 3 |
| 6 | health technology assessment | 3 |
| 7 | health-related quality of life | 3 |
| 8 | healthcare resource utilization | 3 |
| 9 | 23-valent pneumococcal polysaccharide vaccine | 2 |
| 10 | Duchenne muscular dystrophy | 2 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 101 | 1.4 | [Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment](https://doi.org/10.1007/s40273-020-00981-9) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-12-17 | Seamus Kent, Edward Burn, Dalia Dawoud et al. |
| 2 | 46 | 0.4 | [Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis](https://doi.org/10.1007/s40273-017-0529-x) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-06-28 | Steven Simoens, Ira Allen Jacobs, Robert Popovian et al. |
| 3 | 39 | 0.5 | [An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?](https://doi.org/10.1016/j.healthpol.2020.07.007) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2020-07-29 | Chiara L. Whichello, Karin Schölin Bywall, Jonathan Mauer et al. |
| 4 | 34 | 0.4 | [Economic evaluation of meningococcal vaccines: considerations for the future](https://doi.org/10.1007/s10198-019-01129-z) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2019-11-21 | Hannah Christensen, Hareth Al‐Janabi, Pierre Lévy et al. |
| 5 | 32 | 0.8 | [Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations](https://doi.org/10.1007/s40273-023-01297-0) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2023-07-25 | Kumar Mukherjee, Necdet B. Gunsoy, Rita M. Kristy et al. |
| 6 | 31 | 0.4 | [Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives](https://doi.org/10.1007/s40258-021-00637-5) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2021-01-28 | Jingyan Yang, Rongzhe Liu, V. Ektare et al. |
| 7 | 30 | 0.3 | [Vaccination and GDP Growth Rates: Exploring the Links in a Conditional Convergence Framework](https://doi.org/10.1016/j.worlddev.2017.10.013) | [World Development](https://scholar4ai.com/journals/world-development.md) | 2017-11-14 | Neal A. Masia, Jonathan Smerling, Tendayi Kapfidze et al. |
| 8 | 24 | 0.3 | [Health state utilities associated with post-surgical Staphylococcus aureus infections](https://doi.org/10.1007/s10198-019-01036-3) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2019-03-18 | Louis S. Matza, Katherine J. Kim, Holly Yu et al. |
| 9 | 23 | 0.3 | [Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA](https://doi.org/10.1007/s40258-019-00542-y) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2019-12-17 | Mustafa Oguz, Tereza Lanitis, Xiaoyan Li et al. |
| 10 | 23 | 0.3 | [Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase](https://doi.org/10.1007/s41669-020-00240-9) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2020-11-23 | Derek A. Weycker, Aaron Moynahan, Amanda Silvia et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Office Of Health Economics | Government | United Kingdom | 2 |
| 2 | KU Leuven | University | Belgium | 2 |
| 3 | University College Dublin | University | Ireland | 1 |
| 4 | Rutgers, The State University of New Jersey | University | United States | 1 |
| 5 | Intermountain Healthcare | Healthcare | United States | 1 |
| 6 | Universitat de Vic - Universitat Central de Catalunya | University | Spain | 1 |
| 7 | University of Sindh | University | Pakistan | 1 |
| 8 | Merck & Co., Inc., Rahway, NJ, USA (United States) | Company | United States | 1 |
| 9 | Pennsylvania State University | University | United States | 1 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Office Of Health Economics | Government | United Kingdom | 5 |
| 2 | Universidad de Las Palmas de Gran Canaria | University | Spain | 3 |
| 3 | Corvinus University of Budapest | University | Hungary | 3 |
| 4 | London School of Hygiene & Tropical Medicine | University | United Kingdom | 3 |
| 5 | University of York | University | United Kingdom | 3 |
| 6 | University of Sheffield | University | United Kingdom | 3 |
| 7 | Semmelweis University | University | Hungary | 2 |
| 8 | Linköping University | University | Sweden | 2 |
| 9 | Radboud University Nijmegen | University | Netherlands | 2 |
| 10 | University of Alberta | University | Canada | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## Cite this page

Scholar4AI. (2026). Pfizer (United States). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/pfizer-united-states

```bibtex
@misc{scholar4ai-companies-pfizer-united-states,
  author = {{Scholar4AI}},
  title = {Pfizer (United States)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/pfizer-united-states}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).